Your browser is no longer supported. Please, upgrade your browser.
Settings
ADXS [NASD]
Advaxis, Inc.
Index- P/E- EPS (ttm)-0.34 Insider Own0.07% Shs Outstand119.47M Perf Week-15.09%
Market Cap84.22M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float113.37M Perf Month-16.74%
Income-22.60M PEG- EPS next Q- Inst Own14.70% Short Float4.66% Perf Quarter44.46%
Sales1.90M P/S44.32 EPS this Y60.30% Inst Trans5.63% Short Ratio0.44 Perf Half Y67.36%
Book/sh0.45 P/B1.48 EPS next Y- ROA-53.20% Target Price- Perf Year-4.57%
Cash/sh0.26 P/C2.53 EPS next 5Y- ROE-67.10% 52W Range0.26 - 1.57 Perf YTD91.02%
Dividend- P/FCF- EPS past 5Y55.60% ROI-88.00% 52W High-62.42% Beta2.55
Dividend %- Quick Ratio9.90 Sales past 5Y- Gross Margin- 52W Low123.57% ATR0.07
Employees18 Current Ratio9.90 Sales Q/Q53733.30% Oper. Margin- RSI (14)33.51 Volatility7.41% 8.33%
OptionableNo Debt/Eq0.00 EPS Q/Q68.80% Profit Margin- Rel Volume1.11 Prev Close0.67
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume11.91M Price0.59
Recom2.00 SMA20-24.68% SMA50-32.00% SMA2004.18% Volume6,791,932 Change-11.42%
Aug-03-16Reiterated Barclays Overweight $15 → $20
Sep-22-15Initiated Barclays Overweight $40
Sep-11-15Initiated Guggenheim Buy $30
Jun-16-15Reiterated H.C. Wainwright Buy $25 → $30
May-15-15Initiated Jefferies Buy $27
May-14-15Initiated MLV & Co Buy $34
Oct-23-14Initiated H.C. Wainwright Buy $8
Feb-18-14Initiated Aegis Capital Buy $18
Feb-10-14Initiated Noble Financial Buy $12
Apr-12-21 08:30AM  
Apr-10-21 08:31AM  
Apr-05-21 08:00AM  
Mar-25-21 02:45PM  
Mar-23-21 11:33AM  
Mar-16-21 09:00AM  
Mar-12-21 08:00AM  
Jan-25-21 07:00AM  
Jan-19-21 08:00AM  
Dec-22-20 01:42PM  
Dec-16-20 01:05PM  
08:00AM  
Dec-13-20 11:15PM  
Nov-27-20 12:07PM  
11:01AM  
Nov-24-20 08:30AM  
Nov-23-20 04:05PM  
Nov-09-20 08:01AM  
Oct-26-20 08:00AM  
Oct-15-20 08:00AM  
Sep-29-20 08:30AM  
Sep-24-20 08:00AM  
Sep-10-20 08:00AM  
Sep-04-20 04:30PM  
Aug-31-20 05:00PM  
Aug-27-20 08:00AM  
Aug-05-20 09:00AM  
Aug-03-20 09:31PM  
08:00AM  
Jun-23-20 08:00AM  
Jun-17-20 06:25AM  
Jun-11-20 08:00AM  
Jun-01-20 08:00AM  
May-14-20 08:00AM  
Mar-13-20 09:00AM  
Mar-03-20 04:01PM  
Feb-27-20 09:00AM  
Feb-20-20 08:00AM  
Feb-16-20 03:03PM  
Feb-13-20 08:00AM  
Feb-11-20 08:00AM  
Jan-30-20 09:23AM  
Jan-21-20 08:30AM  
Jan-07-20 08:00AM  
Dec-22-19 05:08PM  
Dec-20-19 08:00AM  
05:04AM  
Dec-04-19 08:00AM  
Dec-03-19 08:00AM  
Oct-24-19 09:00AM  
Oct-10-19 08:00AM  
Oct-07-19 08:00AM  
Sep-19-19 06:36AM  
Sep-10-19 07:36AM  
Sep-09-19 08:00AM  
Aug-22-19 08:00AM  
Aug-12-19 06:30AM  
Jul-25-19 11:30AM  
Jul-24-19 07:08AM  
Jul-23-19 08:30AM  
Jul-15-19 08:00AM  
Jun-27-19 06:50AM  
Jun-21-19 10:14AM  
Jun-11-19 09:00AM  
Jun-10-19 04:05PM  
Jun-04-19 08:00AM  
May-25-19 09:48AM  
May-15-19 10:25AM  
08:00AM  
May-14-19 09:00AM  
May-13-19 03:00PM  
May-07-19 09:00AM  
Apr-18-19 05:45PM  
Apr-16-19 10:54AM  
Apr-10-19 08:43AM  
Apr-08-19 09:30AM  
Apr-03-19 04:31PM  
08:19AM  
07:44AM  
07:30AM  
Apr-02-19 04:05PM  
09:44AM  
Apr-01-19 04:31PM  
03:18PM  
02:27PM  
12:20PM  
12:11PM  
08:00AM  
Mar-30-19 09:32AM  
Mar-29-19 03:00PM  
Mar-28-19 01:00PM  
10:41AM  
Mar-27-19 10:54AM  
Mar-25-19 09:25AM  
08:00AM  
Mar-22-19 09:30AM  
Mar-13-19 03:00PM  
08:45AM  
Mar-12-19 08:13AM  
08:00AM  
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.